Hepatitis C in Children and Adolescents: State of the Art
Year: 2026
Type: article
Abstract: Hepatitis C virus (HCV) infection is an important cause of chronic liver disease in children and adolescents, despite its often asymptomatic and indolent course. In infants and children, infection is mainly acquired through vertical transmission, while horizontal transmission becomes increasingly relevant during adolescence. The introduction of direct-acting antivirals (DAAs) has revolutionised HCV management, providing highly effective and well-tolerated treatments. Current international guidelines recommend treatment for all children and adolescents aged ≥ 3 years with chronic HCV infection, preferably with pangenotypic, ribavirin-free regimens. Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are the main first-line options. Sofosbuvir plus daclatasvir represents an additional World Health Organization-recommended option, particularly in resource-limited settings. Despite these advances, early diagnosis, treatment adherence, and equitable access to DAAs remain essential to achieve HCV elimination in children.
Source: Pediatric Reports
Institutions: Meyer Children’s Hospital IRCCS, University of Florence
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,930
OpenAlex ID: W7236632927
